Targeting polyamine biosynthesis to stimulate beta cell regeneration in zebrafish

Area of Science:

• Endocrinology
• Regenerative Medicine
• Pharmacology

Background:

• Type 1 diabetes (T1D) involves the destruction of insulin-producing beta cells, with no current methods to reverse or prevent this loss.
• Previous mouse studies indicated that difluoromethylornithine (DFMO) and Imatinib could preserve beta cell function and reverse diabetes, respectively.
• Clinical trials are underway to repurpose DFMO and Imatinib for T1D, but their direct impact on beta cell regeneration is unknown.

Purpose of the Study:

• To investigate the direct effects of DFMO and Imatinib on beta cell regeneration.
• To determine if pharmacological inhibition of polyamine biosynthesis can stimulate beta cell regrowth.

Main Methods:

• Utilized the zebrafish model system to study beta cell regeneration.
• Induced beta cell death in zebrafish embryos and subsequently treated them with DFMO or Imatinib.
• Assessed the impact of treatments on whole-body growth, exocrine pancreas length, and beta cell regeneration.

Main Results:

• Neither DFMO nor Imatinib affected overall zebrafish growth or exocrine pancreas length.
• Imatinib treatment showed no effect on beta cell regeneration.
• DFMO treatment significantly enhanced beta cell regeneration in zebrafish embryos.

Conclusions:

• Pharmacological inhibition of polyamine biosynthesis using DFMO shows promise for stimulating beta cell regeneration.
• DFMO may represent a novel therapeutic strategy to address beta cell loss in type 1 diabetes.